Kleintje66 schreef op 23 februari 2021 16:23:
endpts.com/neurorx-chief-lines-up-hai...Erg belangrijk verhaal.
Javitt gave Endpoints News a preview of Phase IIb/III data based on an initial 28-day endpoint on Monday afternoon. At 28 days, critically ill Covid-19 patients given NeuroRx and Relief Therapeutics’ aviptadil were 35% more likely to recover and be discharged from the hospital compared to those on a placebo, Javitt said. However, the p-value was 0.08 — falling well below the 0.05 p-value needed to demonstrate statistical significance, meaning there’s a greater chance that the results were random and not tied to the treatment.
“There’s 8 chances in 100 that the difference we observed could have been a random event versus 5 chances in 100,” Javitt said at the time, arguing that the “really strong signal” was median time to recovery and discharge.
At 28 days, the median time to get better and leave the hospital was 10 days shorter for the aviptadil patients, with a p-value of 0.006, Javitt said.
Op basis van die laatste zin heb ik bijgekocht.
Primary Outcome Measures :
Resolution of Respiratory Failure (Composite Endpoint) [ Time Frame: Day 0 through day 28 ]
Cumulative distribution of the time to respiratory failure resolution (without relapse over 7 days) with concurrent survival through day 28
Ik zie niet hoe je sneller beter kunt worden zonder Resolution of Respiratory Failure en de p-value of 0.006 is erg goed. Ik durf de gok nu wel aan.